latest update:
[TrialBase DB]

trial summary · NCT07254793

Prophylactic DLI-X for Leukemia Relapse After HCT

A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

Trial record from the TrialBase DB dataset, status RECRUITING, condition Acute Lymphoid Leukemia, sponsored by University of Arizona. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07254793phase PHASE1enrollment 180start 2026-10-26

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. We hypothesize that pro-DLI-X will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).

Source record: https://clinicaltrials.gov/study/NCT07254793

Facts

registry idNCT07254793
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionAcute Lymphoid Leukemia
sponsorUniversity of Arizona
sponsor classOTHER
enrollment180
start date2026-10-26
primary completion2030-06-01
completion2030-06-01
results postednot reported

Conditions

  • Acute Lymphoid Leukemia
  • Acute Myeloid Leukemia
  • Acute Undifferentiated Leukemia (AUL)
  • Myelodysplastic Syndrome
  • Chronic Myeloid Leukemia
  • Non-Hodgkin Lymphoma

Interventions

  • Exercise Mobilized Prophylactic DLI
  • Standard Prophylactic DLI

Countries

  • United States

Intervention types: BIOLOGICAL

Work with this record